Cost-effectiveness of psychological and pharmacological interventions for generalized anxiety disorder and panic disorder

References

• Mathers C D, Vos T, Stevenson C. The burden of disease and injury in Australia. Australian Institute of Health and Welfare, Canberra 1999
   Google Scholar
• Vanin J R, Vanin S K. Blocking the cycle of panic disorder. Postgraduate Medicine 1999; 105: 141–146
   PubMed Web of Science ®Google Scholar
• World Health Organisation. The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. GenevaSwitzerland 1992
   Google Scholar
• Australian Bureau of Statistics. Mental health and wellbeing: profile of adults, Australia 1997. Australian Bureau of Statistics, Canberra 1998
   Google Scholar
• Therapeutic Guidelines Limited. Therapeutic guidelines: psychotropic 4th edn. Therapeutic Guidelines Limited, Melbourne 2000
   Google Scholar
• Britt H, Miller G, Knox S, et al. Australian Institute of Health and Welfare, Canberra 2001, General practice activity in Australia 2000–01. General Practice Series No. 8
   Google Scholar
• Kapczinski F, Schmitt R, Lima M. The use of antidepressants for generalized anxiety disorder. The Cochrane Library,: Issue 2. Update Software, Oxford
   Google Scholar
• Sheehan D V. Attaining remission in generalized anxiety disorder: venlafaxine extended release comparative data. Journal of Clinical Psychiatry 2001; 62(Suppl. 19)26–31
   PubMedGoogle Scholar
• Gelenberg A J, Lydiard R B, Rudolph R L, Aguiar L, Haskins J T, Salinas E. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial. Journal of the American Medical Association 2000; 283: 3082–3088
   PubMed Web of Science ®Google Scholar
• Rickels K, Pollack M H, Sheehan D V, Haskins J T. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. American Journal of Psychiatry 2000; 157: 968–974
   PubMed Web of Science ®Google Scholar
• Silverstone P H, Salinas E. Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder. Journal of Clinical Psychiatry 2001; 62: 523–529
   PubMed Web of Science ®Google Scholar
• Pollack M H, Zaninelli R, Goddard A. 2001; 62: 350–357
   Google Scholar
• Rocca P, Fonzo V, Scotta M, Zanalda E, Ravizza L. Paroxetine efficacy in the treatment of generalized anxiety disorder. Acta Psychiatrica Scandinavica 1997; 95: 444–450
   PubMed Web of Science ®Google Scholar
• Rudolph L, Entsuah R, Chitra R. A meta-analysis of the effects of venlafaxine on anxiety associated with depression. Journal of Clinical Psychopharmacology 1998; 18: 136–144
   PubMed Web of Science ®Google Scholar
• Caswell A. MIMS, A Caswell. MediMedia Australia, Sydney 2001
   Google Scholar
• Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guideline Team for Panic Disorder and Agoraphobia. Australian and New Zealand clinical practice guidelines for the treatment of panic disorder and agoraphobia. Australian and New Zealand Journal of Psychiatry 2003; 37: 641–656
   PubMed Web of Science ®Google Scholar
• Haby M, Carter R, Mihalopoulos C, Magnus A, Andrews G, Vos T. Assessing Cost-Effectiveness –Mental Health: introduction to the study and methods. Australian and New Zealand Journal of Psychiatry 2004; 38: 569–578
   PubMed Web of Science ®Google Scholar
• Allgulander C, Hackett D, Salinas E. Venlafaxine extended release ER in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study. British Journal of Psychiatry 2001; 179: 15–22
   PubMed Web of Science ®Google Scholar
• Davidson J R, DuPont R L, Hedges D, Haskins J T. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. Journal of Clinical Psychiatry 1999; 60: 528–535
   PubMed Web of Science ®Google Scholar
• Australian Bureau of Statistics. Census data 2000: population by age and sex, Australian states and territories. Australian Bureau of Statistics, Canberra 2001, Time series spreadsheet, 32010.0: Table 9
   Google Scholar
• Angst J, Vollrath M. The natural history of anxiety disorders. Acta Psychiatrica Scandinavica 1991; 84: 446–452
   PubMed Web of Science ®Google Scholar
• Keller M. The long-term clinical course of generalised anxiety disorder. Journal of Clinical Psychiatry 2002; 63(Suppl. 8)11–16
   PubMedGoogle Scholar
• Yonkers K, Dyck I, Warwhaw M, Keller M. Factors predicting the clinical course of generalised anxiety disorder. British Journal of Psychiatry 2000; 176: 544–549
   PubMed Web of Science ®Google Scholar
• Stouthard M, Essink-Bot M, Bonsel G, et al. Disability weights for diseases in the Netherlands. Department of Public Health, Erasmus University, Rotterdam 1997
   Google Scholar
• Sanderson K, Andrews G, Corry J, Lapsley H. Using the effect size to model change in preference values from descriptive health states. Quality of Life Research 2004; 13, in press
   PubMedGoogle Scholar
• Gould R A, Otto M W, Pollack M H. A meta-analysis of treatment outcome for panic disorder. Clinical Psychological Review 1995; 15: 819–844
   Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-IV) 4th edn. American Psychiatric Press, Washington, DC 1994
   Google Scholar
• Borkovec T D, Costello E. Efficacy of applied relaxation and cognitive-behavioral therapy in the treatment of generalized anxiety disorder. Journal of Consulting and Clinical Psychology 1993; 61: 611–619
   PubMed Web of Science ®Google Scholar
• Butler G, Fennell M, Robson P, Gelder M. Comparison of behavior therapy and cognitive behavior therapy in the treatment of generalized anxiety disorder. Journal of Consulting and Clinical Psychology 1991; 59: 167–175
   PubMed Web of Science ®Google Scholar
• Durham R C, Murphy T, Allan T, Richard K, Treliving L R, Fenton G W. Cognitive therapy, analytic psychotherapy and anxiety management training for generalised anxiety disorder. British Journal of Psychiatry 1994; 165: 315–323
   PubMed Web of Science ®Google Scholar
• Ladouceur R, Dugas M, Freeston M, Gagnon F, Thibodeau N. Efficacy of a cognitive behavioural treatment for generalized anxiety disorder: evaluation in a controlled clinical trial. Journal of Consulting Clinical Psychology 2000; 68: 957–964
   PubMed Web of Science ®Google Scholar
• White J, Keenan M. Stress control: a controlled comparative investigation of large group therapy for generalized anxiety disorder. Behavioural Psychotherapy 1992; 20: 97–114
   Web of Science ®Google Scholar
• Deeks J, Altman D, Bradburn M. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. Systematic reviews in health care: meta-analysis in context, 2nd edn., M Egger, G Smith, D Altman. BMJ Publishing Group, London 2001; 285–312
   Google Scholar
• Drummond M, McGuire A. Economic evaluation in health care: merging theory with practice, M Drummond, A McGuire. Oxford University Press, New York 2001
   Google Scholar
• Palisade Corporation. @RISK [computer program] Risk Analysis Add-in for Microsoft Excel. Palisade Corporation, Newfield, NY 2001, Version 4
   Google Scholar
• Otto M W, Pollack M, Maki K M. Empirically supported treatments for panic disorder: costs, benefits and stepped care. Journal of Consulting and Clinical Psychology 2000; 68: 556–563
   PubMed Web of Science ®Google Scholar
• Issakidis C, Sanderson K, Corry J, Andrews G, Lapsley H. Modelling the population cost-effectiveness of current and evidence based optimal treatment for anxiety disorders. Psychological Medicine 2004; 34: 19–35
   PubMed Web of Science ®Google Scholar
• Mahe V, Balogh A. Long-term pharmacological treatment of generalized anxiety disorder. International Clinical Psychopharmacology 2000; 15: 99–105
   PubMed Web of Science ®Google Scholar
• Michelson D, Pollack M, Lydiard R B, Tamura R, Tepner R, Tollefson G. Continuing treatment of panic disorder after acute response: randomised, placebo-controlled trial with fluoxetine. The Fluoxetine Panic Disorder Study Group. British Journal of Psychiatry 1999; 174: 213–218
   PubMed Web of Science ®Google Scholar
• Rapaport M H, Wolkow R, Rubin A, Hackett E, Pollack M, Ota K Y. Sertraline treatment of panic disorder: results of a long-term study. Acta Psychiatrica Scandinavica 2001; 104: 289–298
   PubMed Web of Science ®Google Scholar
• de Beurs E, van Balkom A J, Van Dyck R, Lange A. Long-term outcome of pharmacological and psychological treatment for panic disorder with agoraphobia: a 2-year naturalistic followup. Acta Psychiatrica Scandinavica 1999; 99: 59–67
   PubMed Web of Science ®Google Scholar
• Lader M H, Bond A J. Interaction of pharmacological and psychological treatments of anxiety. British Journal of Psychiatry 1998, Suppl.: 42–48
   Google Scholar
• Perry S. Combining antidepressants and psychotherapy: rationale and strategies. Journal of Clinical Psychiatry 1990; 51(Suppl.)16–20
   PubMedGoogle Scholar
• Mental Health and Suicide Prevention Branch. Better outcomes in mental health care initiative. Australian Department of Health and Ageing, Canberra 2002, (Available at: http://www.health.gov.au/hsdd/mentalhe/boimhc/index.htm Last accessed 12 November 2003.)
   Google Scholar
• Selmi P, Klein M, Greist J, Sorrell S, Erdman H. Computer-administered cognitive-behavioural therapy for depression. American Journal of Psychiatry 1990; 147: 51–56
   PubMed Web of Science ®Google Scholar